News

Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other ...
Sartorius Stedim Biotech has agreed to invest $3m in Nanotein Technologies, a US-based company engaged in the development of ...
In this episode of Denatured, BioSpace’s head of insights Lori Ellis discusses the ‘enormous implications’ of patent policy ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.